Okugawa Yoshinaga, Kitajima Takahito, Yamamoto Akira, Shimura Tadanobu, Kawamura Mikio, Fujiwara Takumi, Mochiki Ikuyo, Okita Yoshiki, Tsujiura Masahiro, Yokoe Takeshi, Ohi Masaki, Toiyama Yuji
Department of Genomic Medicine, Mie University Hospital, Tsu 514-8507, Japan.
Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
J Clin Med. 2022 May 6;11(9):2617. doi: 10.3390/jcm11092617.
Sarcopenia was initially described as a decrease in muscle mass associated with aging and subsequently also as a consequence of underlying disease, including advanced malignancy. Accumulating evidence shows that sarcopenia has clinically significant effects in patients with malignancy, including an increased risk of adverse events associated with medical treatment, postoperative complications, and a poor survival outcome. Colorectal cancer (CRC) is one of the most common cancers worldwide, and several lines of evidence suggest that preoperative sarcopenia negatively impacts various outcomes in patients with CRC. In this review, we summarize the current evidence in this field and the clinical relevance of sarcopenia in patients with CRC from three standpoints, namely, the adverse effects of medical treatment, postoperative infectious complications, and oncological outcomes.
肌肉减少症最初被描述为与衰老相关的肌肉质量下降，随后也被认为是包括晚期恶性肿瘤在内的潜在疾病的结果。越来越多的证据表明，肌肉减少症对恶性肿瘤患者具有临床显著影响，包括与医疗治疗相关的不良事件风险增加、术后并发症以及生存结果不佳。结直肠癌（CRC）是全球最常见的癌症之一，有几条证据表明术前肌肉减少症会对CRC患者的各种结局产生负面影响。在本综述中，我们从医疗治疗的不良影响、术后感染并发症和肿瘤学结局这三个角度总结了该领域的现有证据以及肌肉减少症在CRC患者中的临床相关性。
